Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy

References

• AbramsPSpeakmanMStottMA dose-ranging study of the efficacy and safety of tamsulosin, the first prostate selective alpha 1A-adrenoreceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)Br J Urol199780587969352698
   PubMedGoogle Scholar
• AnderssonSORashidkhaniBKarlbergLPrevalence of lower urinary tract symptoms in men aged 45–79 years:a population-based study of 40,000 Swedish menBJU Int2004943273115291861
   PubMed Web of Science ®Google Scholar
• BarendrechtMMKoopmansRPde la RosetteJJTreatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia:the cardiovascular systemBJU Int200595S1928
   PubMed Web of Science ®Google Scholar
• ChappleCRAl-ShukriSHGattegnoBTamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):efficacy and tolerability in a placebo and active comparator controlled phase 3a studyEur Urol Suppl2005b43344
   Web of Science ®Google Scholar
• ChappleCRChartier-KastlerEPharmacokinetic profile of tamsulosin OCASBJU Int200698S912
   Web of Science ®Google Scholar
• ChappleCRLorenzJMortensenRTamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):efficacy and tolerability in a phase 2b dose-response studyEur Urol Suppl2005a42532
   Web of Science ®Google Scholar
• ChappleCRWyndaeleJJNordlingJTamsulosin, the first prostate-selective alpha 1A-adrenoreceptor antagonist. A meta-analysis of two randomized, placebo controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)Eur Urol199629155678647141
   PubMed Web of Science ®Google Scholar
• DjavanBMilaniSDaviesJThe impact of Tamsulosin Oral Controlled Absorption System (OCAS) on nocturia and the quality of sleep:preliminary results of a pilot studyEur Urol Suppl20054618
   Web of Science ®Google Scholar
• FrankelSJDonovanJLPetersTISexual dysfunction in men with lower urinary tract symptomsJ Clin Epidemiol199851677859743316
   PubMed Web of Science ®Google Scholar
• GormleyGJStonerEBruskewitzRCThe effect of finasteride in men with benign prostatic hyperplasiaN Engl J Med19923271185911383816
   PubMed Web of Science ®Google Scholar
• GupDIShapiroEBaumannMAutonomic receptors in human prostate adenomasJ Urol1990143179851688458
   PubMed Web of Science ®Google Scholar
• KennyBAMillerAMWilliamsonIJEvaluation of the pharmacological selectivity profile of alpha 1 adrenoreceptor antagonists at prostatic alpha 1 adrenoreceptors:binding, functional and in vivo studiesBr J Pharmacol199611887188799556
   PubMed Web of Science ®Google Scholar
• LangerSZPresynaptic regulation of catecholamine releaseBiochem Pharmacol19742317934617579
   PubMed Web of Science ®Google Scholar
• LeporHRole of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasiaProstate Suppl1990375841689172
   PubMedGoogle Scholar
• LeporHGupDIBaumannMLaboratory assessment of terazosin and alpha1 blockade in prostatic hyperplasiaUrology1988322162462301
   PubMed Web of Science ®Google Scholar
• LeporHfor the Tamsulosin Investigator GroupPhase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasiaUrology1998518929009609623
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAJarvisBWagstaffAJTamsulosin. An update of its role in the management of lower urinary tract symptomsDrugs2002621356711790159
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaOMThe long-term effect of Doxazosin, Finasteride, and combination therapy on the clinical progression of Benign Prostatic HyperplasiaN Engl J Med200334923879814681504
   PubMed Web of Science ®Google Scholar
• MichelMCChappleCRComparison of the cardiovascular effects of Tamsulosin Oral controlled Absorption System (OCAS) and Alfuzosin Prolonged release (XL)Eur Urol Suppl2006495019
   Web of Science ®Google Scholar
• MichelMCKorstanjeCKrauwinkelWCardiovascular safety of tamsulosin modified release in the fasting and fed state in elderly healthy subjectsEur Urol Suppl2005a4914
   Web of Science ®Google Scholar
• MichelMCKorstanjeCKrauwinkelWThe pharmacokinetic profile of Tamsulosin oral controlled absorption system (OCAS)Eur Urol Suppl2005b41524
   Web of Science ®Google Scholar
• MichelMCKorstanjeCKrauwinkelWComparison of vascular α1 adrenoreceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulationsEur Urol Suppl2005c44552
   Web of Science ®Google Scholar
• MichelMCKorstanjeCKrauwinkelWCardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the Modified release (MR) formulationEur Urol Suppl2005d45360
   Web of Science ®Google Scholar
• NarayanPEvansCPMoonTLong-term safety and efficacy of Tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaJ Urol203317049850212853808
   PubMed Web of Science ®Google Scholar
• NarayanPO’LearyMPDavidaiGEarly efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia:a randomized open-label trialJ Appl Res2005523745
   Google Scholar
• NarayanPTewariAfor the United States 93-01 Study GroupA second phase III multicenter placebo controlled study of 2 doses of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasiaJ Urol1998160170169783935
   PubMed Web of Science ®Google Scholar
• NordlingJEfficacy and safety of two doses (10 and 15 mg) of alfuzosin of tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasiaBJU Int20059510061215839922
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSchwinnDAα1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasiaJ Urol200417110293514767264
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSiegelRLSafety and efficacy of doxazosin in benign prostatic hyperplasia:a pooled analysis of three double-blind, placebo-controlled studiesUrology199648406158804494
   PubMed Web of Science ®Google Scholar
• SakoKMizumotoTKajiyamaAInfluence of physical factors in gastrointestinal tract on acetaminophen release from controlled-release tablets in fasted dogsInt J Pharm199613722532
   Web of Science ®Google Scholar
• StanleyNThe physiology of sleep and the impact of ageingEur Urol Suppl200531723
   Web of Science ®Google Scholar
• StevensHNSpeakmanMBehaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tractCurr Med Res Opin200622
   Web of Science ®Google Scholar
• van DijkMMde la RosetteJJMCHMichelMCEffects of α1 adrenoreceptor antagonists on male sexual functionDrugs20066628730116526818
   PubMed Web of Science ®Google Scholar
• WiltTJMacDonaldRNelsonDTamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction:a systematic review of efficacy and adverse effectsJ Urol20021671778311743300
   PubMed Web of Science ®Google Scholar
• WiltTJMacDonaldRRutkisITamsulosin for benign prostatic hyperplasiaCochrane Database Syst Rev20031CD00208112535426
   PubMedGoogle Scholar